Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 12.4% – What’s Next?

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) traded down 12.4% on Monday . The stock traded as low as $145.03 and last traded at $137.7250. 34,394 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 282,164 shares. The stock had previously closed at $157.24.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. HC Wainwright boosted their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Stephens restated an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $240.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.53.

Palvella Therapeutics Stock Up 15.9%

The stock has a market cap of $2.06 billion, a P/E ratio of -34.52 and a beta of -0.20. The business has a 50-day simple moving average of $125.66 and a 200-day simple moving average of $115.84.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, analysts predict that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Insider Transactions at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the transaction, the chief operating officer directly owned 2,154 shares in the company, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Jennison Associates LLC lifted its position in shares of Palvella Therapeutics by 262.4% during the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock worth $40,558,000 after purchasing an additional 280,573 shares during the last quarter. Profund Advisors LLC acquired a new stake in Palvella Therapeutics in the 4th quarter valued at approximately $608,000. Lisanti Capital Growth LLC acquired a new stake in Palvella Therapeutics in the 4th quarter valued at approximately $4,341,000. Vanguard Group Inc. increased its position in Palvella Therapeutics by 13.3% in the 4th quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock worth $58,680,000 after buying an additional 65,960 shares during the period. Finally, Fifth Third Bancorp bought a new position in Palvella Therapeutics in the 1st quarter worth approximately $2,486,000. 40.11% of the stock is currently owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.